NASDAQ · Biotechnology · USD
Sagimet Biosciences Inc. (SGMT) Stock Analysis
Sagimet Biosciences Inc. (SGMT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
SGMT Key Statistics
As of Oct 21, 2026Trading
- Open
- $9.76
- Previous Close
- $9.74
- Day's Range
- 9.72–10.21
- 52-Week Range
- 4.50–11.45
- Volume
- 1.58M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 3.49
Valuation
- Market Cap
- $708.38M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.27
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$51.04M
- Shares Outstanding
- 70.34M
- 1-Year Return
- +28.41%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 1.30M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, SGMT closed at $9.99, +28.41% over 1 year.
Sagimet Biosciences Inc. (SGMT) has a market capitalization of $708.38M.
In fiscal 2025, SGMT reported revenue of $0.00.
SGMT Stock Return by Calendar Year
Sagimet Biosciences Inc. (SGMT) return since Jul 2023: what $10,000 became
- 1 year
- $10,000 $12,841
- +28.41%
- 3 years
- $10,000 $20,223
- +102.23%
- Since Jul 2023
- $10,000 $6,263
- −37.37%
If you had invested $10,000 in Sagimet Biosciences Inc. (SGMT) at the close on July 14, 2023, the earliest close on record here, it would have been worth $6,263 at the close on October 21, 2026: −37.37% in total, −13.33% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +68.75% |
| 2025 | +31.56% |
| 2024 | −16.97% |
| 2023 (partial year) | −66.02% |
As of October 21, 2026.
SGMT Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$51.04M | — |
| 2024 | $0.00 | −$45.57M | — |
| 2023 | $2.00M | −$27.88M | −1,393.8% |
| 2022 | $0.00 | −$30.50M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$56.89M | −$51.04M | — |
| 2024 | $0.00 | — | −$54.45M | −$45.57M | — |
| 2023 | $2.00M | — | −$30.74M | −$27.88M | −1,393.8% |
| 2022 | $0.00 | — | −$31.06M | −$30.50M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet
SeekingAlphaAfter Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
YahooSagimet Says Denifanstat Shows Continued Improvement in Acne Through 52 Weeks in China Trial
YahooSagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
YahooSagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11
BenzingaHC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target
Benzinga
All 20 articles ↓Show fewer ↑
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
MarketBeatGuggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26
BenzingaSagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
YahooOppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38
BenzingaCitizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27
BenzingaSagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript
SeekingAlphaSagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise
BenzingaSagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data
InvestorsHubSagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market
StocktwitsSagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell
YahooSagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
YahooSagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
YahooSagimet Biosciences Prices $115M Offer Of Shares And Warrants At $10.00/Unit
BenzingaSagimet Biosciences Suspends And Terminates August 14 Prospectus Supplement Regarding ATM Sales Agreement With Leerink
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B